Fossils unearthed in Grand Canyon reveal new details of evolutionary explosion of life
The newfound remains of fauna from the region suggest that it offered ideal conditions for life to flourish and diversify, in a 'Goldilocks zone' between harsh extremes elsewhere. This evolutionary opportunity produced a multitude of early animals, including oddballs with peculiar adaptations for survival, according to new research.
During the Cambrian explosion, which played out in the coastal waters of Earth's oceans about 540 million years ago, most animal body types that exist today emerged in a relatively short time span, scientists believe.
Back then, the Grand Canyon was closer to the equator, and the region was covered by a warm, shallow sea teeming with burgeoning life — aquatic creatures resembling modern-day shrimp, pill bugs and slugs — all developing new ways to exploit the abundant resources.
Researchers turned to the Grand Canyon's layers of sedimentary rock to unlock secrets of this pivotal moment in the history of life, digging into the flaky, claylike shale of the Bright Angel Formation where most of the canyon's Cambrian-era fossils have been found.
The study team expected to recover mostly the fossilized remains of hard-shelled invertebrates typical of the region. Instead, the team unearthed something unusual: rocks containing well-preserved internal fragments of tiny soft-bodied mollusks, crustaceans, and priapulids, also known as penis worms.
'With these kinds of fossils, we can better study their morphology, their appearance, and their lifestyle in much greater resolution, which is not possible with the shelly parts,' said Giovanni Mussini, the first author of the study published Wednesday in the journal Science Advances. 'It's a new kind of window on Cambrian life in the Grand Canyon.'
Using high-powered microscopes, the team was able to investigate innovations such as miniature chains of teeth from rock-scraping mollusks and the hairy limbs and molars of filter-feeding crustaceans, providing a rare look into the biologically complex ways Cambrian animals adapted to capture and eat prey.
The 'Goldilocks zone' for innovation
For most of the planet's 4 billion-year history, simplicity reigned.
Single-celled microbes remained stationary on the ocean floor, thriving on chemical compounds such as carbon dioxide and sulfur molecules to break down food. What changed?
Scientists still debate what drove the Cambrian explosion, but the most popular theory is that oxygen in the Earth's atmosphere slowly began to increase about 550 million years ago, said Erik Sperling, an associate professor of Earth and planetary sciences at Stanford University.
Oxygen provided a much more efficient way to metabolize food, giving animals more energy to mobilize and hunt for prey, suggested Sperling, who was not involved in the new study.
'The (emergence of) predators kicked off these escalatory arms races, and then we basically got the explosion of different ways of doing business,' Sperling said.
During the Cambrian, the shallow sea covering the Grand Canyon was especially oxygen-rich thanks to its perfect, 'Goldilocks' depth, said Mussini, a doctoral student in Earth sciences at the University of Cambridge in the United Kingdom. Ranging from 40 to 50 meters (about 130 to 165 feet) in depth, the ecosystem was undisturbed by the shoreline's constant waves shifting around sediments, and sunlight was still able to reach photosynthesizing plants on the seafloor that could provide oxygen.
The abundance of food and favorable environmental conditions meant that animals could take more evolutionary risks to stay ahead of their competition, Mussini said.
'In a more resource-starved environment, animals can't afford to make that sort of physiological investment,' Mussini said in a news release from the University of Cambridge. 'It's got certain parallels with economics: invest and take risks in times of abundance; save and be conservative in times of scarcity.'
Many soft-bodied fossil finds before this one have come from regions with harsh environments such as Canada's Burgess Shale formation and China's Maotianshan Shales, noted Susannah Porter, a professor of Earth science at the University of California in Santa Barbara who was not involved in the study.
'It's not unlike if paleontologists far in the future only had great fossil records from Antarctica, where harsh cold environments forced people to adapt. … But then found great human fossils in New York City, where people flourished,' Porter explained. 'We have an opportunity to see different sorts of evolutionary pressures that aren't like, it's really cold, it's really hot, there's not a lot of water.'
Weird adaptations of Cambrian animals
While some of the feeding mechanisms uncovered in the Grand Canyon fossils are still around today, others are much more alien.
Among the most freakish: penis worms that turned their mouths inside out, revealing a throat lined with hairy teeth.
The worms, also known as cactus worms, are mostly extinct today, but were widespread during the Cambrian. The fossilized worm found in the Grand Canyon represents a previously unknown species.
Due to its relatively large size — about 3.9 inches (10 centimeters) — and distinct teeth, it was named Kraytdraco spectatus, after the fictional krayt dragon from the Star Wars universe, Mussini said. This particular penis worm appears to have had a gradient of hundreds of branching teeth used to sweep food into an extendable mouth.
'It's a bit hard to understand how exactly it was feeding,' Mussini said. 'But it was probably eating debris on the seafloor, scraping it away with some of the most robust teeth that it had, and then using these other, more delicate teeth to filter and retain it within this long, tube-like mouth.'
Rows of tiny molars, sternal parts and comblike limbs that once belonged to crustaceans were also among the findings, which all date back 507 million to 502 million years. Similar to today's brine shrimp, the crustaceans used these fine-haired limbs to capture floating food from the water and bring it to the mouth, where molars would then grind down the particles, Mussini explained. Nestled among the molars, researchers even found a few unlucky plankton.
Other creatures resembling their modern counterparts included sluglike mollusks. The fossils revealed chains of teeth that likely helped them scrape algae or bacteria from along the seafloor.
'For each of these animals, there's different components, but most of what we found directly relates to the way these animals were processing their food, which is one of the most exciting parts, because it tells us a lot about their lifestyle, and as a consequence, their ecological implications,' Mussini said.
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
25 minutes ago
- Medscape
Enterosorbent Gel Shows Efficacy in IBS
TOPLINE: Silicolgel, a colloidal silicic acid enterosorbent, was generally safe and well tolerated, and it significantly reduced symptom severity in adults with irritable bowel syndrome, with efficacy being observed in both patients with predominant diarrhoea (IBS-D) and those with mixed bowel habits (IBS-M). METHODOLOGY: Researchers conducted a randomised controlled trial to assess the efficacy, safety, and tolerability of silicolgel in patients with IBS-D and IBS-M. They included 120 adults (mean age, 36.9 years; 66% women) with IBS-D or IBS-M across four regional health centres in Ukraine between March 15, 2023, and August 31, 2023, with a score on the IBS Severity Scoring System (IBS-SSS) of 100-400 points. Patients were randomly assigned to receive either 15 mL of silicolgel (n = 60) or placebo (n = 60) three times daily for 4 weeks, followed by a 4-week no-medication observation phase to assess the return of symptoms. The primary outcome was a reduction in IBS-SSS scores by ≥ 50 points after 4 weeks of treatment, indicating a clinically meaningful improvement in symptoms. Patients used daily diaries to track bowel habits, IBS symptoms (including abdominal pain and bloating), and quality of life. TAKEAWAY: After 4 weeks, the proportion of patients achieving at least a 50-point reduction in the IBS-SSS score was significantly higher in the silicolgel group than in the placebo group (91.67% vs 20%; relative risk [RR], 4.58; P < .0001). The silicolgel group showed a significantly greater decrease in the mean IBS-SSS score, from 255.62 at baseline to 92.75 after 4 weeks, than the placebo group that showed a change from 254.42 at baseline to 257.58 after 4 weeks (P < .001). Among patients with IBS-D and IBS-M, those on silicolgel vs placebo achieved the primary outcome (RR, 4.77 and 4.44, respectively; P < .0001 for both). Significant reductions in mean severity scores were noted for IBS symptoms from baseline to week 4 with silicolgel. All adverse events were mild and non-serious, noted at one site, and found unrelated to treatment, with no treatment discontinuations observed. IN PRACTICE: "Silicolgel is a widely available and affordable enterosorbent treatment, providing safe and effective relief of symptoms in patients with IBS-D and IBS-M. Based on these findings, its use should be considered more widely for frontline therapy of IBS-D and IBS-M," the authors of the study wrote. SOURCE: This study was led by O. Kuzminska, Chernivtsi Hospital of Emergency Medical Care, Chernivtsi, Ukraine. It was published online on July 25, 2025, in Neurogastroenterology & Motility. LIMITATIONS: Silicolgel is not absorbed and works locally in the gut, beginning to exert its effect immediately. Thickeners could not be used in the placebo because they affect the gut, so the viscosity of the placebo was a white, watery solution. Additionally, the treatment was limited to 28 days as silicolgel's licence permits a continuous dosing period of not more than 4 weeks. DISCLOSURES: This study was supported by FW Medical Ltd, the owner of silicolgel, and Delta Medical LLC, the distributor of silicolgel in Ukraine. They had no direct involvement in the study. One author reported being a consultant for the owner company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
25 minutes ago
- Medscape
SSRIs and SNRIs Boost Clozapine Treatment Response
TOPLINE: Standard doses of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) reduced the risk for relapse when added to clozapine in treatment-resistant schizophrenia, unlike other antidepressants, according to a new study. Sertraline, duloxetine, and escitalopram were particularly effective, and high-dose antidepressant use increased both psychiatric and somatic hospital admission risks. METHODOLOGY: Researchers analysed and then meta-analysed data from two register-based, nationwide cohort studies in Finland (1996-2017) and Sweden (2006-2023) and included 23,206 patients with schizophrenia (mean age, 41.3 years; 9531 women) who were followed up from first clozapine use until death or the end of data linkage. This study had a within-individual cohort design in which each person served as their own control and compared clozapine augmentation with specific antidepressants against clozapine use alone. Researchers categorised antidepressant use into four dose categories: low (< 0.6 defined daily doses [DDDs] per day), standard (0.6 to < 1.1 DDDs per day), medium-high (1.1 to < 2.1 DDDs per day), and high (≥ 2.1 DDDs per day), with specific milligrams per day ranges for each medication. The primary outcome was schizophrenia relapse, defined as hospital admission with psychotic disorder; the secondary outcome was somatic hospital admission. The mean follow-up duration was 12.1 years for the Finnish cohort and 11.4 years for the Swedish cohort. TAKEAWAY: A total of 65.8% of patients in the Finnish cohort and 51.0% in the Swedish cohort had a relapse during follow-up. Additionally, 52.6% of patients in the Finnish cohort and 41.2% in the Swedish cohort experienced hospital admission because of somatic reasons during follow-up. The lowest risk for relapse was observed with sertraline (adjusted hazard ratio [aHR], 0.76), followed by duloxetine (aHR, 0.78) and escitalopram (aHR, 0.85; P < .001 for all). Antidepressants other than SSRIs and SNRIs were associated with an increased risk for relapse without achieving statistical significance. Standard doses showed optimal effectiveness, with sertraline 30-54 mg/d (aHR, 0.49; 95% CI, 0.27-0.89), escitalopram 6-10 mg/d (aHR, 0.57; 95% CI, 0.37-0.88), and duloxetine 18-32 mg/d (aHR, 0.59; 95% CI, 0.46-0.75) showing the lowest risk for relapse. Augmentation with antidepressants was not associated with an increased risk for somatic hospital admission at low or standard doses; however, high-dose use was linked to elevated risks for both relapse and somatic hospital admission. IN PRACTICE: "[The study] findings support the use of SSRIs and SNRIs as viable augmentation strategies for clozapine-treated patients with schizophrenia, particularly at standard doses," the authors wrote. "The same finding was not observed with other, non-SSRI and non-SNRI antidepressants," they added. "The findings have important clinical implications, emphasising the potential utility of antidepressant augmentation in specific subgroups of patients with TRS [treatment-resistant schizophrenia], such as those with persistent negative symptoms, comorbid depression, or suicidal ideation. Given the increased risks associated with high-dose antidepressant use, clinicians should carefully balance the potential benefits with the risk of adverse outcomes," they concluded. SOURCE: This study was led by Heidi Taipale, PhD, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. It was published online in the August 2025 issue of The Lancet Psychiatry. LIMITATIONS: This study was limited by its observational design, the lack of randomisation, and the low number of users for some exposures. This study lacked information on why antidepressants were started or stopped, symptom severity fluctuations, social support or non-pharmacologic interventions, and confirmation of treatment resistance. Additionally, dose categorisation on the basis of DDDs was not optimal for some drugs. Schizophrenia relapse was broadly defined as hospital admission with psychotic disorder without symptom specificity, and major depressive disorder was rarely recorded. Furthermore, the findings were limited to long-term risks in low-cost healthcare settings, and people with lived experience were not involved. DISCLOSURES: This study received funding from the Sigrid Jusélius Foundation and the Finnish Ministry of Social Affairs and Health. This project used data from the REWHARD consortium supported by the Swedish Research Council. Several authors reported having financial ties with various sources including pharmaceutical companies. Details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Associated Press
an hour ago
- Associated Press
OncoX Deepens ABVC Alliance
CEO Yen Wen Pin's IPO Vision Gains Traction as OncoX Expands Pipeline SILICON VALLEY, CA - August 1, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ('Company'), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today shared a strategic update on its ongoing collaboration with OncoX BioPharma, Inc., a rising oncology player that has licensed four IND-stage drug assets from ABVC. The two companies have taken another step forward, as OncoX continues to unlock funding to support product advancement under its bold, innovation-driven roadmap. Led by its CEO, Mr. Yen Wen Pin, OncoX has leveraged its core competencies in natural product innovation and dietary supplements to build a unique position in oncology. The Company is actively translating its strengths into a pipeline of immunotherapy-driven treatments supported by ABVC's IND-stage programs. Mr. Yen's strategic vision includes building long-term revenue streams through therapeutic innovation and cross-sector expansion. 'We are building OncoX with a long-term vision to deliver real value to patients and investors,' said Mr. Yen Wen Pin, CEO of OncoX BioPharma. 'Through the licensed INDs from ABVC and continued collaboration, we're pushing forward innovative therapies that will anchor our strategy and will help facilitate our momentum, stability, and strong identity in the cancer therapeutics space.' OncoX's platform centers around immunotherapy-inspired cancer treatments derived from ABVC's clinical-stage portfolio. Each program represents a carefully selected opportunity - designed not for the sake of headlines, but for real progress. OncoX has deliberately raised capital in phases, allocating it directly to the development of these candidates. Its recent funding efforts have led to the fulfillment of an additional milestone payment, a sign of both operational discipline and intent. 'We view this partnership as a case study in how smart biotech collaborations can grow over time,' said Dr. Uttam Patil, ABVC's Chief Executive Officer. 'OncoX's consistent execution has translated into steady licensing revenue for ABVC and increasing momentum around these oncology programs. We're optimistic about what the next chapters will bring.' Including this latest milestone, ABVC and its subsidiaries have now recorded a total of $1.396 million in cumulative licensing income from OncoX and other strategic partners, including AiBtl BioPharma and ForSeeCon Eye Corporation. With each step forward, OncoX brings new definition to its roadmap - blending innovation with pragmatism, and aligning business development efforts with the scientific potential of its pipeline. OncoX remains focused on developing not only drug candidates, but a revenue-generating model grounded in credibility and commercial viability. About OncoX BioPharma OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company currently has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has demonstrated promising safety and efficacy in early-phase clinical studies and received four INDs (Investigational New Drug Applications) approved by the U.S. FDA. The Company believes that the estimated total market opportunity of its oncology pipeline, inclusive of its existing licensing agreements and assets, is significant. In addition to its therapeutic pipeline, OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. The company has also acquired the Lycogen(R) extraction platform to enter adjacent fields including preventative medicine, chronic disease care (such as benign prostatic hyperplasia, diabetic wound healing), aesthetic medicine, and animal health. These cross-sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research. [1] OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility. The company is expanding its global footprint, with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets. OncoX is currently preparing for future clinical milestones and pursuing long-term international partnerships to bring its innovative therapies to patients worldwide. [1] About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Uttam Patil Email: [email protected]